NICE joins forces with Canadian peer to offer scientific advice to the pharma industry

pharmafile | February 6, 2019 | News story | Research and Development, Sales and Marketing CADTH, Canada, NICE, UK, pharma 

NICE has announced a collaboration with its Canadian counterpart, the Canadian Agency for Drugs and Technology in Health (CADTH), with the goal of offering the pharma industry parallel scientific advice so that they may better develop robust health technology assessment (HTA) applications.

Specifically, the two agencies will seek to educate companies on how to offer value-based clinical and economic evidence to support the regulatory submissions of their products, offering feedback on such submissions alongside expert advice from clinicians, health economists and patient representatives.

This feedback and advice will take the form of separate advice reports from both organisations as well as a joint summary which will help firms evaluate the effectiveness of their submissions and prepare for future HTAs.

“We recognise the inherent difficulties faced by developers in designing clinical trial programmes that meet the precise requirements of multiple international markets,” explained Jeanette Kusel, Director of NICE Scientific Advice. “This new collaboration with CADTH uses the synergies between the English and Canadian systems and provides companies with comprehensive and practical advice from both countries through a single, streamlined process.”

Michelle Mujoomdar, Acting Vice President, Evidence Standards at CADTH, added: “This exciting new international collaboration between two established HTA bodies will help pharmaceutical companies develop relevant evidence for CADTH and NICE while streamlining the process of obtaining advice in two distinct markets.”

Matt Fellows

Related Content

NICE approves first treatment for obstructive HCM for NHS use

The National Institute for Health and Care Excellence (NICE) has announced that it has approved …

NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks

The National Institute for Health and Care Excellence (NICE) has announced that it has recommended …

NICE recommends Kapruvia for treatment of moderate-to-severe CKD-associated pruritus

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics have announced that the National …

Latest content